Icon
+91 94997 68112
Login Register

Vimpat - (100MG ; 150MG ; 200MG ; 50MG Tablet)

LACOSAMIDE UCB pharma
100MG ; 150MG ; 200MG ; 50MG Tablet
Less Than $1000 mn
More Than 5
More Than 5
Less Than 5
Less Than 5
More Than 5
More Than 5
VIMPAT is indicated in patients 17 years and older with partial-onset seizures as monotherapy or adjunctive therapy.
Yes
****, ******, ********, *******, ******, ******, *********, ************, *****, *****, *** (*******), ******, ***** *** ****** *** *** *** ***** **** ***** **** ** **** ****** '*** (******** ** ***** **, ****) . ***** ********** **** ********, ******, ****** *** *** ****** *** ******* **** **** **** ****** ****** *** ******* ****** ***** **, ****. *** ********** ********* **** ***** ********* ***** **** ******** ***** & ******* ******* ***** *** ****** ** ***** *** *********. ** **** ** *** ********* *** ****** ****** ***** **, ****. ******** *************** ***** ***** * **** *********** *** ********** ** ****** '*** ***** *** ******** ** ****. **** ****** *** ****** ** *****. **** *** ******* **** ** * ************ *********** *** *** *** ********* ***** ** ***** ****** ** **** *** ****** ********* *********. ****: ******** **** ***** ** ****** ********* ** *** ** ****** $*.** ******* ** ****.
Vimpat Patent 1
***** ****** ******* ***** **** ** **
**** ******* ***** **** ** **
****** ******* ***** **** ** **
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ** *** **, **** ******* ***** **** ** ** ******** ***** ***** ****
**** *** \ ** *** **, **** ******* ***** **** ** ** ********* ******** ***** ***** ****
****** *** \ ** *** **, **** ******* ***** **** ** ** **** ***** ***** ****
  1. *** **, **** : ******, ********, *******, ******, ******, *********, ************, *****, *****, *******, ***, ******, ***** *** ****** ***** * **** ** **** ****** ‘*** (******** ** ***** **, ****)
  2. *** **, **** : **** ******** *** ****** ***** *** **** ** *** ****** **** ****** '*** (******** ** ***** **, ****).
  3. *** **, **** : ***** ****** ******** *** ****** ***** *** **** ** *** ****** **** ****** '*** (******** ** ***** **, ****).
  4. *** **, **** : *** ****** ***** * **** ******* ***** ****** ** ******** ***** ** **.
  5. *** **, **** : *** ***** * **** ******* **** ** ******** ***** ** ********.
  6. *** **, **** : *** ***** * **** ******* ******, ********, *******, ******, ******, *********, ************, *****, *****, *** (*******), ******, ***** *** ****** ** ******** ***** ** ********
  7. *** **, **** : ********** **** ******** *** ********* ** ******** ********* *** **** ** ** **** ***.
  8. *** *, **** : *** ***** * **** ******* *** ** ******** ******** ***** ** *** ***** **** ** **** ****** '*** (******** ** ***** **, ****).
  9. ***** **, **** : ********** *** ********* **** *** (*******) *** ********* ** *** ********* **** ** ** **** ***.
  10. :
  11. *** **, **** : ********** *** ********* **** ****** ***** *** ***** ** ********* *** *** ***** *** ***** ****** *** ********* *** **** ** ** **** ***.
  12. *** *, **** : ********** *** ********* **** ****** *** ********* ** ****** ********* **** ** ** **** ***.
  13. *** **, **** : ******** *************** ***** * **** *********** **** ****** '*** ***** *** ******** ** ****.
  14. *** **, **** : ******** ***** * **** ******* ********* *** ****** ********** ** *** ******* ********* ***** **** ** **** ****** '*** *** ****** **** ********.
  15. *** *, **** : ***** ***** ****** '*** ** ***** *** ********* ** *** ******** *** ********** ********* **** *** ******* *********
  16. *** **, **** : ******** ***** * **** ******* ***** ****** ** ** ***** **** ** **** ****** '*** *** ****** **** ********.
  17. *** **, **** : **** ****** ********* ********** ** ********, *****, ************ & *******.
  18. *** **, **** : ******* ******* ******** ******* *****'* ******** **** ****** '*** ** ***** *** ********* ** ********.
  19. *** **, **** : ******** ***** * **** ******* ***** ****** ******* *** ****** '*** ** ******* ****** ***** *** *** **** ******* ** ***** ******'* ****** **** ******** **** ** ****.

Vimpat - (200 mg/ 20 ml; Intravenous, Solution)

LACOSAMIDE UCB pharma
200 mg/ 20 ml; Intravenous, Solution
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
More Than 5
More Than 5
VIMPAT is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).
Yes
***** ****** ** ***. ***** ****** ***** * **** ** ** ****** '*** *** *** *********. *****, ********** ******* **** ***** ******. ********* ** ********** ***** ****** **** ****** ******* ***** ********** ** ****** '***. (*.*. ***** ***** **, ****)
Vimpat Patent 1
***** ****** *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ** ***** *, **** ******* ******** ******** ** *** **, ****
  1. *** **, **** : ***** ****** ******** *** ****** ***** **'* **** ** ****** ** ****** '***.
  2. *** *, **** : *** ****** ***** * ********* ******* ***** ****** ** ****** '***.
  3. *** **, **** : * ********* ** ******* ** ***** **
  4. *** **, **** : *** ****** ******* **** ***** ******, ********* ** ********** ***** ****** **** ****** ******* ***** ********** ** ****** '***. (*.*. ***** ***** **, ****)

Vimpat - (10mg/ml; Oral Solution)

LACOSAMIDE UCB pharma
10mg/ml; Oral Solution
Less Than $1000 mn
Less Than 5
More Than 5
More Than 5
Less Than 5
More Than 5
More Than 5
VIMPAT is indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Yes
********, ******, ****** ******** *** ****** ***** **'* **** ** **** ****** *** ****** **** ********. *** ***** * ******* ******* ********, ******, ****** ****** ************ ** ****** '***. ******* ****** ******** *** ****** ***** **** ** **** ****** *** ****** **** ******** *** *** ************ *********. ****, ********** ******* **** *** **** ** ******, *** ******** ***'* ****** ******* ****** ***** ****.********* ********* ******* ** ******, ********, ******. **** ***** ** *** **** *********, ****** *** ***** ****** **** ********* *** ****** **** ******** **** ****** '***. *** ****** **** ****** '*** ** ***** ** ********** ** **** ****** ******* *** **** ********.
Vimpat Patent 1
****** ******* ***** **** ** **
******** ******* ***** **** ** **
****** ******* ***** **** ** **
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* ***** **** ** ** ******** ************ ******** ** *** **, ****
******** *** \ ** *** **, **** ******* ***** **** ** ** ********* ******** ***** ***** ****
****** *** \ ** *** **, **** ******* ***** **** ** ** ******** ******** ** *** **, ****
  1. *** *, **** : ******** *** **** * ****** ** ************* *** **** **. ****** ** *** *** ***
  2. *** **, **** : ****** **** * ****** ** ************* *** **** **. ****** ** *** *** ***
  3. *** **, **** : ****** **** ****** ** ************* *** **** **. ****** ** *** *** ***
  4. *** **, **** : *** ***** ******* ******* ******, ********, ****** ******** ************ ** '*** ******, ********** ******** *** *** *** ** *********** ** ********* *******. ***** ******* ********, ****** ****** ***** ***
  5. *** **, **** : ****** **** * ****** ** ************* *** **** **. ****** ** *** ( '*** ****** ** ******** ** ***)
  6. *** **, **** : ********* ********* **** ********, ***** *** ***** ** ********** *** *** *****.
  7. *** **, **** : *** ***** ******* ******* ****** ******** ************ ** '*** ******
  8. **/**/**** : ** ****** ** ******
  9. *** **, **** : ******** ***** * **** ******* ********* *** ****** ********** ** *** ******* ********* ***** **** **** ****** '*** *** ****** **** ********.
  10. *** **, **** : ******** ***** * **** ******* ***** ****** ** ** ***** **** ** **** ****** '*** *** ****** **** ********.
  11. *** *, **** : * ********* ** ******* ** ***** ** *** ****** *** ******* *** *** ******** **** '*** ****** ** ********* ** *** ******* *********. **** ********** ******* **** *** ******* *********.
  12. *** **, **** : ******* ******* ******** ******* *****'* ******** **** ****** '*** ** ***** *** ********* ** ********.
  13. *** **, **** : ******** ***** * **** ******* ***** ****** ******* *** ****** '*** ** ******* ****** ***** *** *** **** ******* ** ***** ******'* ****** **** ******** **** ** ****.
  14. *** **, **** : ********* ******* ********* **** ****** ' ***, ** *** ****************** *** ****** **** ***** ***** ****

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.